Belvaux, Luxembourg – May 8, 2025

Invitrolize, a Luxembourg-based biotech startup, has secured seed funding from Expon Capital’s Digital Tech Fund to accelerate the global rollout of ALIsens®, the first in vitro model capable of identifying respiratory sensitizers under realistic exposure conditions.

Developed over more than a decade of research at LIST. Inbound demand has grown consistently by 200% annually over the past 3 years.

“This is not just a better model – it’s a leap forward in how industries can protect human health.” said Jérôme Wittamer, Managing Partner at Expon Capital.